tiprankstipranks
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX

Vertex Pharmaceuticals Stock Forecast & Price Targets

4,237 Followers
See the Price Targets and Ratings of:

Analyst Rating Consensus

Moderate Buy
17Ratings
10 Buy
7 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

Analyst Price Target on VRTX

Average Price Target

$292.88
▼(-4.14% Downside)
Based on 17 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $292.88 with a high forecast of $365.00 and a low forecast of $250.00. The average price target represents a -4.14% change from the last price of $305.53.
Highest Price Target$365.00Average Price Target$292.88Lowest Price Target$250.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
J.P. Morgan
$319.00
Buy
4.41%
Upside
Initiated
JPMorgan assumes Vertex (VRTX) at OverweightJPMorgan analyst Jessica Fye assumes coverage on Vertex (NASDAQ: VRTX) with a Overweight rating and a price target of $319.00.
Piper Sandler
$256.00
Hold
-16.21%
Downside
Reiterated
Piper Sandler Maintains Neutral on Vertex Pharmaceuticals, Raises Price Target to $256
Cantor Fitzgerald
$365.00
Buy
19.46%
Upside
Initiated
Cantor Fitzgerald Initiates Coverage On Vertex Pharmaceuticals with Overweight Rating, Announces Price Target of $365
BMO Capital
$325.00
Buy
6.37%
Upside
Reiterated
Vertexs (VRTX) ViaCyte Acquisition "Adds Additional Shots on Goal" - BMO Capital reiterates Stock at Outperform with $325 Price TargetBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $325.00 price target on Vertex (NASDAQ: VRTX), following the companys announcement of ViaCyte acquisition.
Argus Research
$280.00
Buy
-8.36%
Downside
Reiterated
Vertex Pharmaceuticals price target raised to $280 from $275 at ArgusVertex Pharmaceuticals price target raised to $280 from $275 at Argus
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PRVAPrivia Health Group
RXDXPrometheus Biosciences
ROIVRoivant Sciences
ABCLAbCellera Biologics
NRIXNurix Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

FAQ

What is VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is $292.88.
    What is VRTX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for VRTX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

        What's Included in PREMIUM?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis